Navigation Links
Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
Date:2/6/2008

SUNNYVALE, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will announce financial results for the fourth quarter and full year 2007 after the markets close on Thursday, Feb. 28, 2008. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)

John Bishop, Chief Executive Officer, and Michael Myhre, Vice President, Corporate Controller, will host the conference call to discuss Cepheid's financial results and business highlights. David Persing M.D., Ph.D., Executive Vice President and Chief Medical and Technology Officer, and Robert Koska, Senior Vice President Worldwide Commercial Operations, will also participate in the Q-and-A portion of the call.

Interested participants and investors may access the teleconference call by dialing 888-680-0860 (U.S./Canada) or 617-213-4852 (international), participant code 58037054. A telephonic replay will be available for seven days beginning at 6:30 p.m. Eastern Time. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 29481680. Callers can also pre-register for the call through the following link: https://www.theconferencingservice.com/prereg/key.process?key=PUEA9KDFL

The webcast of the call can be accessed on the Investor section of Cepheid's Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download, and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Cepheid's Web site for 90 days.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
2. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
3. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
4. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
5. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
6. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
7. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
9. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
10. WorldHeart Schedules Teleconference
11. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2019)... ... November 04, 2019 , ... ... development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health ... GPEx® Boost. The technology enhances Catalent’s proven GPEx expression platform through multiple ...
(Date:11/2/2019)... ... October 31, 2019 , ... A clinical trial usually ... other: study managers, principal investigators, supply chain managers, manufacturers, IRT, CRAs and so ... of the latest data, potentially leading to patient risk. , By having a ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma to kill cancer ... South Dakota School of Mines & Technology are exploring new ways to regulate ... , If successful, the technique would prove to be a drug-free, minimally invasive ...
(Date:10/29/2019)... ... October 29, 2019 , ... Modality Solutions, ... and cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November ... , The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology ...
Breaking Biology Technology:
(Date:10/30/2019)... ... October 29, 2019 , ... ... kits, for SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in ... UA, UTP, and UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using ...
(Date:10/30/2019)... BALTIMORE, Md. (PRWEB) , ... October 30, 2019 ... ... at the 12th Annual CBRNe Convergence in Nashville, TN from Tuesday, November 5, ... and military responses to CBRNe (chemical, biological, radiological, nuclear) and IED (explosive) threats. ...
(Date:10/30/2019)... ... October 30, 2019 , ... ... exhibit self-assembly properties and bioactivity that are encoded by the ordering of ... peptides in the shift of the sidechain attachment to the backbone amide-nitrogen ...
Breaking Biology News(10 mins):